StockWatch
·

Anupam Rasayan India Ltd Q2 FY27 Results

ANURASQ2 FY27 Results
Filing
Result:Steady· Market: Up#Margin expansion
MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue805.9323.1%10.2%
Total Income821.1723.0%11.1%
Expenditure731.7122.4%10.3%
PBT89.4628.4%18.4%
Net Profit64.9726.9%13.7%
OPM23.23%1.56pp4.66pp
NPM7.91%0.24pp0.18pp
EPS4.3929.5%11.7%
View full financials

Chemicals sector reads core revenue/PAT growth and margin trend — consolidated PAT +13.7% and OPM expansion look decent, but the 10.2% revenue growth is mostly inorganic (Jayhawk acquisition, not in year-ago base) while organic growth missed management's own 25% guidance by a wide margin and standalone revenue fell 32% YoY, so this is in-line/ordinary quality rather than a standout.

Q2 FY-2027 RESULTS · ANURAS

Anupam Rasayan: consolidated PAT +14% YoY on M&A scale-up; standalone revenue -32%

PAT +13.68% YoY · revenue +10.19% · margins expanding

06 Nov 2026 · 3 min read
Revenue

₹805.94 Cr

+10.19% YoY

PAT (consolidated)

₹64.97 Cr

+13.68% YoY

Net margin

7.91%

+0.2pp YoY

EPS

₹6.81

Anupam Rasayan's consolidated PAT (profit after tax for the period, pre-minority) was ₹64.97 Cr in Q2 FY27, up 13.7% YoY from ₹57.15 Cr and up 26.9% QoQ from ₹51.22 Cr; profit attributable to owners was ₹50.03 Cr (basic EPS ₹6.81 versus ₹3.93 a year ago). Consolidated revenue was ₹805.94 Cr, up 10.2% YoY and 23.1% QoQ. The YoY comparison isn't like-for-like, though: Jayhawk Fine Chemicals (US, acquired effective February 27, 2026) wasn't fully in the year-ago consolidation base, so a meaningful share of the reported YoY growth is inorganic rather than organic volume growth.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹805.94 Cr+23%+10.2%
Expenses₹731.71 Cr+22.4%+10.3%
PAT₹64.97 Cr+26.86%+13.68%
Net margin7.91%+0.2pp+0.2pp
EPS₹6.81+100.9%+73.3%

The standalone (parent-only) numbers tell a different story. Standalone revenue fell 32.4% YoY to ₹397.19 Cr from ₹587.93 Cr, yet standalone PAT still rose 10.3% YoY to ₹45.65 Cr because cost of materials consumed fell even faster than revenue, pushing standalone OPM to 31.6% from 18.6% a year ago — a richer revenue mix rather than volume growth, with the year-ago quarter likely carrying a large, lower-margin order. At the consolidated level, OPM was 23.2%, expanding from 18.6% YoY but compressing from 24.8% in Q1 FY27; NPM was 7.9%, modestly ahead of both the prior quarter (7.7%) and year-ago quarter (7.7%). Non-controlling interests absorbed ₹14.94 Cr of the ₹64.97 Cr consolidated PAT, reflecting the partly-owned Tanfac, Jayhawk and now Bliss GVS Pharma structure.

₹
1,068.691,123.741,178.81,233.861,288.911,162.908-0308-2509-1710-1211-0411-06Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹1,162.9, down 0.2% over the past month of trading.

₹ Cr
024.2648.5172.7748.46Q1 FY26rev ₹486 Cr57.15Q2 FY26rev ₹731 Cr60.59Q3 FY26rev ₹512 Cr56Q4 FY26rev ₹636 Cr51.22Q1 FY27rev ₹655 Cr64.97Q2 FY27rev ₹806 Cr
Quarterly consolidated PAT, ₹ Crore

For context: this is the second-highest quarterly PAT of the last 6 quarters.

What management guided (1 FY-2027 call)
FY27 organic revenue growth 25% ± couple points; standalone EBITDA 24-26%, consolidated 22-24%; capex INR 70-80 Cr. Expect working capital improvement; order book to contribute 25-30% of revenue.

— This quarter: missed

Management's August 2026 guidance called for FY27 organic revenue growth of 25% ± a couple of points, standalone EBITDA margin of 24-26% and consolidated EBITDA margin of 22-24%. The margin targets were met or beaten this quarter (standalone 31.6%, consolidated 23.2%), but the growth target was missed by a wide margin — consolidated revenue grew only 10.2% YoY and leaned on acquisitions rather than organic volumes, while standalone (the core organic business) revenue actually contracted. We found no quarter-specific Street consensus to benchmark this print against. The quarter's biggest corporate event — the ₹1,750 Cr, 48.2%-stake acquisition of Bliss GVS Pharma, effective September 28, 2026 — barely touched this quarter's P&L (3 days consolidated, ~₹1.2 Cr PAT) but added ₹10,224 Cr of provisional goodwill to the balance sheet; its first full quarter of contribution, alongside a full-year Jayhawk contribution, falls in Q3 FY27.

  • W1

    First full quarter of Bliss GVS Pharma consolidation in Q3 FY27, against management's pro-forma group revenue guidance of ₹4,000+ Cr annualised (Anupam standalone ~₹1,676 Cr + Tanfac ~₹711 Cr + Jayhawk ~₹722 Cr + Bliss GVS ~₹927 Cr)

  • W2

    Whether consolidated revenue growth closes the gap to management's 25% organic FY27 target — H1 FY27 growth is tracking well below that, and much of it is inorganic

  • W3

    Durability of standalone's 31.6% OPM (up from 18.6% YoY) — watch whether this margin jump holds or reverts as order mix normalises

Informational and educational content only. Not investment advice.